Gyros and George Washington University step up collaboration

17-Dec-2003

Gyros AB revealed today that its collaboration with George Washington University to evaluate and develop the recently launched Gyrolab Bioaffy™ is being stepped up, after a successful feasibility phase.

Gyrolab Bioaffy is a solution for protein quantification, based on Gyros technology platform, in which single or multiplex immunoassays are performed at nanoliter scale in CD microlaboratories. Dr. Benjamin Dickens, Associate Research Professor, George Washington University has been evaluating the performance of Gyrolab Bioaffy in comparison with conventional techniques, initially using mouse samples.

“We routinely have to assay proteins in extremely small amounts of sample,” explained Dr. Dickens, “Current technologies are not optimized for small volumes so the ability to work at nanoliter scale on Gyrolab Bioaffy can be a tremendous advantage. Preliminary data was very promising and assay development appears to be fast and straightforward, so we are extending the study to human samples and focusing on the potential to monitor multiple analytes in a single sample.”

Maris Hartmanis, CEO at Gyros AB, explained, “Collaborations such as these give us an excellent opportunity to see our products used under realistic laboratory conditions. The work has progressed smoothly and both partners are happy to continue in order to gain even more data of high scientific quality.”

Hartmanis continued, “We are confident that our approach to miniaturization and integration of immunoassays will enable maximum information to be gained from minimum amounts of sample. To have this substantiated by independent scientists is of great value to us.”

About George Washington University

The George Washington University Medical Center (GWUMC) is an internationally recognized, interdisciplinary academic health care center comprising the School of Medicine and Health Sciences; School of Public Health and Health Services; GW Hospital, which is jointly operated by Universal Health Services, Inc. (UHS); and GW Medical Faculty Associates, Inc. (MFA) which includes both the primary care and specialty practices of the medical faculty. GWUMC also has a longstanding tradition in research, with about 400 research projects currently underway. GWUMC is especially known for its Cancer Institute (GWCI), Response to Emergencies and Disasters Institute (READI), Institute for Spirituality and Health (GWISH), Ronald Reagan Institute for Emergency Medicine (RRIEM), Center for Health Policy, minimally invasive surgery, and cardiovascular research and treatment.

For further information, visit www.gwumc.edu

 


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.